Last reviewed · How we verify
Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors (COMBINATION)
The aim of the COMBINATION trial is to prospectively study the sequential approach of using afatinib combined with a short course of chemotherapy, followed by osimertinib, upon progression and acquisition of a T790M mutation, also combined with a short course of chemotherapy.
Details
| Lead sponsor | Amsterdam UMC, location VUmc |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 5 |
| Start date | Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Apr 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Non-Small Cell Lung Cancer
Interventions
- Afatinib, Osimertinib, Carboplatin and Pemetrexed
Countries
Netherlands